Q Earnings: $5.8 billion (+83%) YTD Revenues: $48.6 billion (flat) YTD Earnings: $15.3 (+14%) Comments: KEYTRUDA sales were up 10% to $8.1 billion driven by continued global demand and uptake in ...

Global biopharmaceutical sales were $16.3 billion, down 6%. Primary Care sales were down 16% to $7.6 billion. Eliquis sales were up 22% to $2.0 billion. Prevnar sales were down 3% to $1.7 billion.

3Q Earnings: $186 million (earnings were $1.6B 3Q24) YTD Revenues: $44.5 billion (+8%) YTD Earnings: $2.4 billion (-44%) ...

TandemAI has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced ...

Merck has entered a definitive agreement to acquire Cidara Therapeutics, a biotechnology company developing drug-Fc conjugate ...

The U.S. Department of Health and Human Services (HHS) and the U.S. FDA, has appointed Richard Pazdur, M.D., as director of ...

Cytovance Biologics, a CDMO serving the biopharmaceutical industry, recently celebrated its 20th anniversary in Oklahoma City.

Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, appointed Carlos Martin as Chief ...

JSR Life Sciences LLC has entered into a definitive agreement to transfer Crown Bioscience Inc. to Adicon Holdings Limited.

Domain Therapeutics, a clinical-stage biopharmaceutical company, has appointed Jean-Marie Cuillerot, M.D., as Chief Medical ...

Panthera Biopartners, a UK Site Management Organization (SMO) which runs commercial clinical trials for the pharmaceutical ...

Tech transfer in oral solid dose (OSD) manufacturing is one of the most critical, and often underestimated, phases in the ...